SHX 022
Alternative Names: SHX-022Latest Information Update: 22 Dec 2022
At a glance
- Originator Guangzhou Dazhou Biomedicine
- Class Antihyperglycaemics; Cardiovascular therapies; Obesity therapies; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Diabetes mellitus; Obesity
Most Recent Events
- 21 Nov 2022 Preclinical trials in Cardiovascular disorders in USA (PO) (Guangzhou Dazhou Biomedicine pipeline, November 2022)
- 21 Nov 2022 Preclinical trials in Diabetes mellitus in USA (PO) (Guangzhou Dazhou Biomedicine pipeline, November 2022)
- 21 Nov 2022 Preclinical trials in Obesity in USA (PO) (Guangzhou Dazhou Biomedicine pipeline, November 2022)